Thus, all the TIS phenotypes responded exquisitely to the BCL-XL-targeting ABT-263/navitoclax and A1331852 BH3 mimetics except for the less sensitive palbociclib-TIS cancer cells. This evidence concerns the gene BCL2L1 and cancer.